Study: Zoledronic acid inhibits bone growth

04/25/2013 | AAFP News Now

Researchers found osteoporosis drug zoledronic acid increases levels of a biomarker that inhibits bone formation in postmenopausal women. The study was published in the Journal of Clinical Endocrinology & Metabolism. Lead author Antonino Catalano, M.D., said patients who use zoledronic acid may need other treatments to allow for new bone formation.

View Full Article in:

AAFP News Now

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Financial Officer
B. E. Smith
Miramar, FL
Director of ASO Department
Bluegrass Family Health
Lexington-or could be in Nashville, TN, KY
Claims Director
PacificSource
Springfield, OR
Mgr NGS Provider Enrollment (I)
National Government Services - WellPoint
Harrisburg, PA
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA